Tobi Thomas

Tobi Thomas is a journalist who has received the Scott Trust bursary and reports on scientific and medical topics. They grew up during a time of austerity and have covered issues related to healthcare, education, and public services. Their writing often highlights the impact of government policies on these areas and explores the material inequalities between generations. Thomas is committed to reporting on innovative ideas that address climate change, social justice, and inclusive society.

99%

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

98%

Examples:

  • The author consistently reports on scientific and medical topics without any evidence of bias.
  • The author does not make any value judgments or express personal opinions in their reporting.

Conflicts of Interest

100%

Examples:

  • There is no evidence of any conflicts of interest in the author's reporting.

Contradictions

100%

Examples:

  • In another article, the author reports on a study that found the weight loss drug semaglutide could reduce heart attack risk by 20%.
  • In one article, the author reports on a study that found the Moderna combined flu and Covid-19 vaccine offered better protection than current vaccines.

Deceptions

100%

Examples:

  • The author does not use any deceptive practices in their reporting.

Recent Articles

Moderna's Promising Two-in-One Flu and COVID-19 Vaccine: Higher Immune Responses in Late-Stage Trials

Moderna's Promising Two-in-One Flu and COVID-19 Vaccine: Higher Immune Responses in Late-Stage Trials

Broke On: Monday, 10 June 2024 Moderna's experimental two-in-one vaccine, mRNA-1083, shows higher immune responses to both flu strains and SARS-CoV-2 in older adults compared to separate vaccines in a late-stage clinical trial. The combination shot could offer convenience and potentially hit the market as early as fall 2025.
New Weight Loss Drug Semaglutide Reduces Cardiovascular Risk by 20%: Preliminary Findings from Two Studies

New Weight Loss Drug Semaglutide Reduces Cardiovascular Risk by 20%: Preliminary Findings from Two Studies

Broke On: Monday, 13 May 2024 A major medical breakthrough: Semaglutide, a weight loss drug, reduces heart attack, stroke, or death due to cardiovascular disease risk by 20% according to two studies presented at the European Congress of Obesity. The medication's potential cardiovascular benefits could make it a game-changer for treating heart conditions in millions across the UK.
New Weight Loss Drug Semaglutide Reduces Cardiovascular Risk by 20%: Preliminary Findings from Two Studies

New Weight Loss Drug Semaglutide Reduces Cardiovascular Risk by 20%: Preliminary Findings from Two Studies

Broke On: Monday, 13 May 2024 A major medical breakthrough: Semaglutide, a weight loss drug, reduces heart attack, stroke, or death due to cardiovascular disease risk by 20% according to two studies presented at the European Congress of Obesity. The medication's potential cardiovascular benefits could make it a game-changer for treating heart conditions in millions across the UK.